GlassScriptPhysician profile
Gregory T Stallworth
NPI 1043314057
$2,039.68
in general payments reported to CMS, 2019-2025
21 companies · $148 in 2025
The $148 reported for 2025 was more than what 75% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $352 · 2021: $458 · 2022: $421 · 2023: $153 · 2024: $136 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.31 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $246.63 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $221.45 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.16 | 2021-2025 | |
| Janssen Biotech, INC. | $199.77 | 2021-2022 | |
| Abbott Laboratories | $140.20 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Amarin Pharma, INC. | $66.08 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $61.27 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $60.36 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $53.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.77 | 2019 | |
| Smith+Nephew, INC. | $49.09 | 2019-2020 | |
| Abbvie INC. | $48.31 | 2023-2025 | Linzess, Viberzi |
| Lilly USA, LLC | $38.18 | 2019-2021 | |
| Melinta Therapeutics, LLC | $25.64 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $21.88 | 2019 | |
| Allergan, INC. | $16.30 | 2019 | |
| Dexcom, INC. | $13.67 | 2025 | Dexcom G6 Transmitter |
| Vyera Pharmaceuticals, LLC | $11.31 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.08 | 2019 | |
| Pfizer INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Stallworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.